十年耕耘结硕果，跨界融合启新程，第十届医药创新与投资大会将于2025年10月26-27日在南京丰大国际大酒店盛大召开，大会初版日程今日正式发布，聚 焦全球医药前沿与资本动向，汇聚医药创新与投资领域的顶尖智慧，为参会者呈现一场跨界融合的思想盛宴。 会议信息 会议时间：2025年10月26-27日 会议地点：南京江北新区丰大国际大酒店 本次大会涵盖多个专题论坛，覆盖创新药研发、临床研究、细胞与基因治疗、投资并购、资本市场和商保政策等多个热点领域，特邀权威专家与知名投资 人，分享行业洞见、解读政策趋势、探讨合作机遇。 | 简版日程 | | | | --- | --- | --- | | 10月26日上午 | | | | 第十屆零有创新 | | | | 与投资大会开幕式 | | | | (敬请期待) | | | | 10月26日(下午) | | | | 分会场1 | 分会场2 | 分会场3 | | 细胞与基因治疗 | 减重创新 | 临床数据 | | 前沿论坛 | 研发论坛 | 全球直发专场 | | 分会场4 | 分会场5 | 分会场6 | | 抗肿瘤 | 矢药 | 创新转化与 | | 新药论坛 | 数智化论坛 | 临 ...

Group 1 - The company announced the establishment of a new partnership for investment in the pharmaceutical industry, involving its wholly-owned subsidiary Beihai Ruizhi Venture Capital Co., Ltd. [1] - The total committed capital for the new partnership, Shenzhen Luohu Donghai Ruizhi Pharmaceutical Industry Partnership (Limited Partnership), is set at 200 million yuan, with Beihai Ruizhi contributing 58 million yuan, representing 29% of the total commitment [1]

Core Viewpoint - East China Pharmaceutical (000963.SZ) aims to enhance its industrial investment ecosystem and expand its industry chain layout by establishing a partnership with Shanghai Fuguang Private Fund Management Co., Ltd. and other investors to create a specialized pharmaceutical industry investment fund totaling RMB 2 billion [1] Group 1: Investment Details - The total committed capital for the specialized pharmaceutical industry investment fund is RMB 2 billion, with East China Pharmaceutical contributing RMB 980 million, representing a 49% stake [1] - The fund will focus on investment areas including innovative drugs, medical aesthetics, health and wellness, animal health, and sectors related to biology, medicine, and health that align with Hangzhou's five major industrial ecosystems [1]

Group 1 - The company, Huadong Medicine (000963.SZ), announced its participation as a limited partner in a new investment fund, "Hangzhou Fuguang Hongze Equity Investment Partnership (Limited Partnership)" [1] - The total committed capital for the fund is RMB 2 billion, with the company contributing RMB 980 million, representing a 49% stake [1] - The investment focus of the fund includes innovative pharmaceuticals, medical aesthetics, health and wellness, animal health, and other sectors related to biology, medicine, and health that align with Hangzhou's five major industrial ecosystems [1]

Core Viewpoint - China Resources Pharmaceutical (03320) is collaborating with partners to establish a fund with an expected scale of RMB 500 million, focusing on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] Company Summary - The company plans to commit a total investment of up to RMB 123 million, which represents approximately 24.6% of the total committed capital for the fund [1] - The fund is expected not to be accounted as a subsidiary of the company after its establishment [1] - Shenzhen China Resources Capital is anticipated to be appointed as the fund manager [1]

Core Viewpoint - The agreement outlines the terms for the issuance of shares by Ruizhi Medical Technology Co., Ltd. to Jiangmen Ruilian Medical Investment Co., Ltd. for the year 2024, including share transfer and ownership changes [1][2][3]. Group 1: Share Issuance Agreement - The agreement was signed on April 1, 2025, between Ruizhi Medical Technology Co., Ltd. and Jiangmen Ruilian Medical Investment Co., Ltd. [1] - The total registered capital of Ruizhi Medical is RMB 497.96 million, with a total share count of 100% held by MEDICAL LIMITED [1]. - WOO SWEE LIAN, the actual controller, currently holds 5.11% of the shares, with an additional 4.56% held by MEGA STAR [1]. Group 2: Share Transfer and Ownership Changes - Following a court ruling, WOO SWEE LIAN and his associates will hold 15.70% of the shares after the forced transfer of 30,033,098 shares from another shareholder [2]. - After the completion of a share transfer agreement, WOO SWEE LIAN and his associates will collectively own 21.18% of the shares, maintaining his position as the controlling shareholder [3]. Group 3: Subscription Details - The agreement allows for the issuance of up to 60,019,704 shares, representing 30% of the total share capital prior to the issuance, at a price of RMB 5.27 per share [4][5]. - The subscription amount will be determined by the number of shares multiplied by the issuance price, with funds sourced legally by the subscriber [5]. - The shares subscribed will have a lock-up period of 18 months post-issuance [5]. Group 4: Legal and Compliance - The agreement is subject to approval from the board of directors and shareholders, as well as regulatory approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission [7]. - Any modifications to the agreement must be documented in writing and comply with legal procedures [7][8].